Cargando…

PPAR𝛾 Gene and Atherosclerosis: Genetic Polymorphisms, Epigenetics and Therapeutic Implications

Atherosclerosis is the leading cause of mortality and morbidity in the developed world. It is characterized by the formation of a plaque in the walls of middle and large arteries leading to macrovascular complications. Several risk factors are included, with diabetes being one of the most important...

Descripción completa

Detalles Bibliográficos
Autores principales: Grbić, E, Peterlin, A, Kunej, T, Petrovič, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231320/
https://www.ncbi.nlm.nih.gov/pubmed/30425909
http://dx.doi.org/10.2478/bjmg-2018-0011
_version_ 1783370198827401216
author Grbić, E
Peterlin, A
Kunej, T
Petrovič, D
author_facet Grbić, E
Peterlin, A
Kunej, T
Petrovič, D
author_sort Grbić, E
collection PubMed
description Atherosclerosis is the leading cause of mortality and morbidity in the developed world. It is characterized by the formation of a plaque in the walls of middle and large arteries leading to macrovascular complications. Several risk factors are included, with diabetes being one of the most important for the onset and development of atherosclerosis. Due to an increase in the prevalence of diabetes in the world, the incidence of diabetic complications (microvascular and macrovascular) is increasing. Peroxisome proliferator-activated receptor γ (PPARγ) plays a important role in atherosclerotic processes. Peroxisome proliferator activated receptor γ belongs to the superfamily of nuclear receptors, has a great presence in fat tissue, macrophages, and regulates gene expression and most of the processes that lead to the onset and development of atherosclerosis. In this review, we discuss the basic patho-physiological mechanisms of atherosclerosis in type 2 diabetes mellitus (T2DM). Furthermore, we discuss the impact of PPARγ polymorphisms, and the epigenetic mechanisms affecting the onset of atherosclerosis, i.e, DNA methylation and demethylation, histone acetylation and deacetylation, and RNA-based mechanisms. Moreover, we add therapeutic possibilities for acting on epigenetic mechanisms in order to prevent the onset and progression of atherosclerosis.
format Online
Article
Text
id pubmed-6231320
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Sciendo
record_format MEDLINE/PubMed
spelling pubmed-62313202018-11-13 PPAR𝛾 Gene and Atherosclerosis: Genetic Polymorphisms, Epigenetics and Therapeutic Implications Grbić, E Peterlin, A Kunej, T Petrovič, D Balkan J Med Genet Original Article Atherosclerosis is the leading cause of mortality and morbidity in the developed world. It is characterized by the formation of a plaque in the walls of middle and large arteries leading to macrovascular complications. Several risk factors are included, with diabetes being one of the most important for the onset and development of atherosclerosis. Due to an increase in the prevalence of diabetes in the world, the incidence of diabetic complications (microvascular and macrovascular) is increasing. Peroxisome proliferator-activated receptor γ (PPARγ) plays a important role in atherosclerotic processes. Peroxisome proliferator activated receptor γ belongs to the superfamily of nuclear receptors, has a great presence in fat tissue, macrophages, and regulates gene expression and most of the processes that lead to the onset and development of atherosclerosis. In this review, we discuss the basic patho-physiological mechanisms of atherosclerosis in type 2 diabetes mellitus (T2DM). Furthermore, we discuss the impact of PPARγ polymorphisms, and the epigenetic mechanisms affecting the onset of atherosclerosis, i.e, DNA methylation and demethylation, histone acetylation and deacetylation, and RNA-based mechanisms. Moreover, we add therapeutic possibilities for acting on epigenetic mechanisms in order to prevent the onset and progression of atherosclerosis. Sciendo 2018-10-29 /pmc/articles/PMC6231320/ /pubmed/30425909 http://dx.doi.org/10.2478/bjmg-2018-0011 Text en © 2018 Grbić E, Peterlin A, Kunej T, Petrovič D, published by Sciendo http://creativecommons.org/licenses/by-nc-nd/3.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
spellingShingle Original Article
Grbić, E
Peterlin, A
Kunej, T
Petrovič, D
PPAR𝛾 Gene and Atherosclerosis: Genetic Polymorphisms, Epigenetics and Therapeutic Implications
title PPAR𝛾 Gene and Atherosclerosis: Genetic Polymorphisms, Epigenetics and Therapeutic Implications
title_full PPAR𝛾 Gene and Atherosclerosis: Genetic Polymorphisms, Epigenetics and Therapeutic Implications
title_fullStr PPAR𝛾 Gene and Atherosclerosis: Genetic Polymorphisms, Epigenetics and Therapeutic Implications
title_full_unstemmed PPAR𝛾 Gene and Atherosclerosis: Genetic Polymorphisms, Epigenetics and Therapeutic Implications
title_short PPAR𝛾 Gene and Atherosclerosis: Genetic Polymorphisms, Epigenetics and Therapeutic Implications
title_sort ppar𝛾 gene and atherosclerosis: genetic polymorphisms, epigenetics and therapeutic implications
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231320/
https://www.ncbi.nlm.nih.gov/pubmed/30425909
http://dx.doi.org/10.2478/bjmg-2018-0011
work_keys_str_mv AT grbice pparγgeneandatherosclerosisgeneticpolymorphismsepigeneticsandtherapeuticimplications
AT peterlina pparγgeneandatherosclerosisgeneticpolymorphismsepigeneticsandtherapeuticimplications
AT kunejt pparγgeneandatherosclerosisgeneticpolymorphismsepigeneticsandtherapeuticimplications
AT petrovicd pparγgeneandatherosclerosisgeneticpolymorphismsepigeneticsandtherapeuticimplications